UPDATE: Oppenheimer Lowers PT to $57 on DeVry

A report from Oppenheimer reiterates it Outperform rating and lowers it price target from $70 to $57 on DeVry (NYSE: DV).

The report states, “September total enrollment decreased 0.9% y/y. Despite DeVry Undergrad & Carrington concerns, positive growth in enrollment occurred at all currently reporting segments, with DeVry Graduate total enrollment +2% y/y, DeVry Medical (Ross/AUC aggregate) new/total enrollments +23%+6% y/y, and DeVry Brasil new/total enrollments +29%/+18% y/y. We anticipate Chamberlain growth to remain solid."

DV closed yesterday at $46.08.